Recursion Pharmaceuticals Q2 EPS $(0.38) Misses $(0.37) Estimate, Sales $11.02M Miss $11.91M Estimate
Portfolio Pulse from Benzinga Newsdesk
Recursion Pharmaceuticals (NASDAQ:RXRX) reported Q2 losses of $(0.38) per share, missing the analyst consensus estimate of $(0.37) by 2.7%. The company's quarterly sales were $11.02 million, missing the analyst consensus estimate of $11.91 million by 7.5%. However, this represents a 43.56% increase over sales of $7.67 million the same period last year.
August 08, 2023 | 12:00 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Recursion Pharmaceuticals reported Q2 losses and sales that missed analyst estimates. However, sales increased by 43.56% compared to the same period last year.
Recursion Pharmaceuticals missed both EPS and sales estimates, which could negatively impact the stock price in the short term. However, the significant YoY sales growth might mitigate some of the negative impact.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100